about
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AMutation update and genotype-phenotype correlations of novel and previously described mutations in TPM2 and TPM3 causing congenital myopathiesNeuroprotective effect of erythropoietin against pressure ulcer in a mouse model of small fiber neuropathyPotential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis[Electron microscopy as a tool for the diagnosis of neuropathies].[Usefulness of skin biopsy in the diagnosis of small fiber neuropathy].Too many numbers and complexity: time to update the classifications of neurogenetic disorders?Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.Successful treatment of human herpesvirus 6 encephalomyelitis in immunocompetent patient.Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational StudyIntravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation.The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2.Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series.Stem cells, progenitors and myelin repair.The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection.Fibroblast growth factors in oligodendrocyte physiology and myelin repair.Contribution of electron microscopy to the study of neuropathies associated with an IgG monoclonal paraproteinemia.Evidence-based treatment of chronic immune-mediated neuropathies.An update on nerve biopsy.Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition.Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies.Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies.Nerve biopsy: requirements for diagnosis and clinical value.Recommendations for useful serum testing with suspected multiple sclerosis.Recommendations for a definition of multiple sclerosis in support of early treatment.Recommendations for the management of multiple sclerosis relapses.Central and peripheral neurological complications of primary Sjögren's syndrome.Peripheral neuropathies in rheumatic disease--a guide to diagnosis.Endoneurial fibroblast-like cells.Neuropathologic characterization of INF2-related Charcot-Marie-Tooth disease: evidence for a Schwann cell actinopathy.Therapeutic options in Charcot-Marie-Tooth diseases.Skin innervation: important roles during normal and pathological cutaneous repair.Charcot-Marie-Tooth diseases: an update and some new proposals for the classification.Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials.Classifications of neurogenetic diseases: An increasingly complex problem.Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.[TRPV1 in neuropathic pain: from animal models to therapeutical prospects].[Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome]Phenotypic variability in giant axonal neuropathy.
P50
Q22000603-99FA707B-AE36-4970-BFFF-8DB370288C1AQ28237280-BEBAED2E-00E4-4FC3-8343-2734F02F6BE3Q28545182-9DDF9D08-0913-4882-BD84-71051F64B4C6Q30567342-915A41A2-B355-41BE-AFEC-6812314CAF64Q33393190-10979385-4BC0-466F-A5B2-041E9D131B1AQ34111602-3074E0A5-886A-4BBB-A6D4-85817C9B30EBQ34674228-C88F244E-6D39-41C6-9D8D-30E02BDF18C2Q35625820-061E8A12-9F0F-4B33-940C-AC3B21B02608Q35880221-F2701B64-C8C6-4232-983D-63530B89324EQ35915998-3DE6A495-544F-4ABF-A47A-32BBB76ABB2CQ36085055-ACDE6988-E30E-436B-BBA8-25ED06C3473BQ36121607-18FC164A-EED6-465C-B796-6E72758CCADCQ36151870-7AE25FB3-86E8-451F-A28B-12804986A285Q36268469-F23FCE2D-5629-4651-A82B-8941BA5F4731Q36297679-B6AC4EE3-1521-4BAA-9C13-2F8D26256A8AQ36326016-B508825F-5A54-49B2-8621-1B2D0A8F8F80Q36732868-9669AC23-5CCF-44DF-A9B8-85DE855F51D8Q37550515-4829DF6F-D094-491D-8B16-1D42B3230F05Q37552680-E3D8339E-8513-47FF-B250-D38D2593DE30Q37714082-FD47F8DE-3ACB-4FC0-BB4F-E2FD62C5E7D8Q37805699-EEE02DAB-E1A1-4AEC-8715-654378C222ADQ37820842-DA1B4EFB-7238-4E71-B41A-5E46A346F3C5Q37835738-E370A8C0-D374-45A7-B5CD-677815A7A4E4Q37983224-E0ABA9AA-C11B-424B-937A-395077427D4CQ37991462-7988907A-1790-44E5-BF97-3F2C0459434AQ38007286-9E6ECB3E-DB53-4B87-8697-523A7B40C4C3Q38030161-4F5142EB-849D-402A-9092-58F5B861D5D0Q38036106-0CB34326-E94E-4DE1-B4A2-D1DFBAB9DD8FQ38055320-2AC0770C-ECCB-4030-BE75-5F895BFD71D1Q38309247-92AE3D60-A942-43B2-BCDE-1DB094983A7AQ38363677-A363611E-B0B9-416E-B8CA-C620017F9414Q38387406-D7B5411D-03B0-4099-87D6-8FE71E19E6AEQ38561514-642AC9C4-015A-4482-B065-B544AAB750A2Q38711142-99C26010-8C2C-4512-8C0C-818A2FBB8437Q38725329-C50CBFAC-B05B-41FD-9096-8FA025D1B9ACQ38848386-34FB9C15-F507-41FA-A2C7-8FFCC7DD7649Q38856824-DECFF6F3-760E-48F1-BDF0-FC4299632DE2Q39223754-47FE9A5E-0DAB-48DB-B612-B76AE91C5A1CQ39375610-AC0D4EA5-2125-4887-895E-821ACD1E54CBQ39514911-D184693E-7168-45F2-8356-07BC491965B9
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Laurent Magy
@ast
Laurent Magy
@en
Laurent Magy
@es
Laurent Magy
@fr
Laurent Magy
@nl
Laurent Magy
@sl
type
label
Laurent Magy
@ast
Laurent Magy
@en
Laurent Magy
@es
Laurent Magy
@fr
Laurent Magy
@nl
Laurent Magy
@sl
prefLabel
Laurent Magy
@ast
Laurent Magy
@en
Laurent Magy
@es
Laurent Magy
@fr
Laurent Magy
@nl
Laurent Magy
@sl
P214
P106
P108
P21
P213
0000 0004 3083 2975
P214
P31
P496
0000-0003-1784-2901
P735
P7859
viaf-172824216